Latest news with #DaewoongPharmaceutical
Korea Herald
10 hours ago
- Business
- Korea Herald
CGBio launches China joint venture to expand regenerative medicine reach
Korean regenerative medicine company CGBio, affiliated with Daewoong Pharmaceutical, announced Monday the establishment of Sol Cent Bio Co. Ltd., a joint venture with Chinese orthopedic device maker Shanghai Sanyou Medical, marking its full-scale entry into the Chinese regenerative medicine market. The new company will localize the production of advanced regenerative products and medical devices, including human tissue grafts and stem cell isolation systems, to meet China's growing clinical demand. Shanghai Sanyou Medical, a publicly listed company specializing in spinal and trauma care devices, brings strong manufacturing capabilities and a nationwide hospital network to the partnership. By combining CGBio's proprietary technologies with Sanyou's local expertise, Sol Cent Bio aims to accelerate regulatory approvals and build a stable supply chain within China. Initial offerings will include allogeneic bone grafts and acellular dermal matrices, widely used in bone regeneration, burn care and reconstructive surgery. The venture will also produce stem cell separation systems and other regenerative tools developed by CGBio and its subsidiary, CGMedtech. Through the joint venture, CGBio aims to expand its global footprint and deliver regenerative solutions tailored to Chinese patients and providers, while improving cost competitiveness under China's volume-based procurement system. 'The joint venture with Sanyou Medical marks a strategic shift, combining our technology with local manufacturing and sales strength,' said CGBio CEO Yu Hyun-seung. 'Local production will enhance supply stability and responsiveness, setting a new standard in Asia's regenerative medicine market.'
Korea Herald
4 days ago
- Business
- Korea Herald
Daewoong launches Nabota in Qatar, strengthens K-beauty in Middle East
Daewoong Pharmaceutical has officially launched its botulinum toxin product Nabota in Qatar, further strengthening its expansion into the Middle Eastern market, the company announced Thursday. The launch was marked by a symposium in Doha on May 30, where Nabota's entry into the Qatari market was formally announced. With this addition, Nabota is now available in all three key Gulf countries at the heart of the K-beauty trend: Qatar, Saudi Arabia and the United Arab Emirates. These nations represent high-potential markets, due to their high per capita income and growing interest in cosmetic and aesthetic procedures. Qatar, for example, had a per capita gross domestic product of around $80,000 in 2024, and demand for premium botulinum toxin products is rising quickly. According to Daewoong, the Qatar launch symposium attracted around 200 local medical professionals. 'Nabota is distinguished by its rapid and precise effects, making it the ideal product for Nabolift procedures that not only reduce wrinkles but also refine facial contours and expressions," Koo Bon-cheol, director of Naeum Dermatology and a featured speaker at the event, said. 'Given the limited number of botulinum toxin products currently registered in Qatar, the event highlighted the strong interest in Nabota among Middle Eastern health care providers,' Abdulkader Ramo, general practitioner from the UAE said. Meanwhile, Daewoong Pharmaceutical has also developed Nabolift, a proprietary technique that uses microinjections of botulinum toxin to promote lifting, reduce wrinkles and stimulate collagen production. The company plans to launch marketing campaigns across Qatar and the UAE that highlight differentiated procedures like the Nabolift, while strengthening its partnerships with local collaborators. 'The launch is meaningful in that it establishes Qatar as a new strategic foothold in the Middle East,' said Yoon Joon-soo, head of Daewoong's Nabota Business Division. 'We plan to further expand across the region by leveraging Nabota's high-quality performance and our exclusive treatment methods like Nabolift.'
Yahoo
6 days ago
- Business
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
18-04-2025
- Health
- Korea Herald
Daewoong expands type-2 diabetes treatment Envlo to Latin America, Russian markets
Daewoong Pharmaceutical said Friday that it has submitted regulatory applications for its type 2 diabetes medication Envlo (enavogliflozin) in seven countries, including six in Latin America — Costa Rica, Honduras, the Dominican Republic, Panama, El Salvador and Guatemala — as well as Russia and the other members of the Commonwealth of Independent States. Envlo is Korea's first domestically developed SGLT-2 (sodium-glucose co-transporter 2) inhibitor, a class of drugs that lowers blood sugar by promoting the excretion of glucose and sodium through urine. In addition to glycemic control, the drug has shown benefits for blood pressure, kidney function, cardiovascular health and weight management. Clinical trials have demonstrated that Envlo outperforms global competitor dapagliflozin in key indicators, including glycated hemoglobin (HbA1c), fasting blood glucose, urinary glucose-to-creatinine ratio (UGCR) and insulin resistance (HOMA-IR). According to pharmaceutical market research firm IQVIA, the diabetes treatment market in Latin America and the region encompassing Russia and the Commonwealth of Independent States reached a combined 7 trillion won ($4.9 billion) in 2023. The SGLT-2 inhibitor segment, which includes Envlo, saw especially rapid growth — doubling in Latin America and rising 142 percent in Russia and the other CIS members. In response to this demand, Daewoong is accelerating its global rollout. Envlo is now registered or under regulatory review in 19 countries. 'Our goal is not just market expansion but delivering innovative diabetes care globally,' said Daewoong CEO Park Seong-soo. 'We are committed to strengthening Envlo's presence and achieving our vision of entering 30 countries by 2030.'
